Meeting
2011 ASCO Annual Meeting
Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
Authors
A. M. P. Omuro
Memorial Sloan-Kettering Cancer Center, New York, NY
A. M. P. Omuro , K. Beal , S. Karimi , D. Correa , T. A. Chan , L. M. DeAngelis , I. T. Gavrilovic , C. Nolan , A. Hormigo , A. B. Lassman , T. J. Kaley , I. K. Mellinghoff , C. Grommes , K. Panageas , A. S. Reiner , R. Barradas , L. E. Abrey , P. H. Gutin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00782756
Citation
J Clin Oncol 29: 2011 (suppl; abstr 2028)
Abstract #
2028
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Final results of a single-arm phase II study of bevacizumab and temozolomide following radiochemotherapy in newly dignosed adult glioblastoma patients.
First Author: Martin Kelly Nicholas
Poster
2011 ASCO Annual Meeting
CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma.
First Author: V. Verschaeve
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2020 ASCO Virtual Scientific Program
Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.
First Author: Wenyin Shi